DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20212933

Thorough QT/QTc (TQT) study

Lakshmi Balasundaram, Bharatraj Kidambi, Surya Singaravelu

Abstract


With a number of drugs entering the market, cardiac safety remains a cause of major concern for the regulatory authorities, before approval. The incidence of drug induced arrhythmia with non-cardiovascular drugs is low, however the result is fatal, hence much focus is being given to assess the pro-arrhythmic potential of a drug. The arrhythmogenic risk of the drug is higher if the patient is on polypharmacy or has other risk factors such as an electrolyte imbalance or an underlying structural heart disease. QT prolongation can be either due to congenital causes such as Long QT syndromes (LQTS) which include Romano-Ward syndrome, Jervell and Lange-Nielson syndrome or can be acquired, which is mainly due to drugs. Several drugs such as terfenadine, astemizole, cisapride and grepafloxacin have been withdrawn from the market due to QT prolongation and development of a fatal ventricular arrythmia - torsades de pointes (TdP). This has led to implementation of guidelines to assess cardiac safety. The pro-arrhythmic risk can be assessed using thorough QT/QTc studies or exposure response modelling of intensive ECGs. This article will give an overall view of the use of QT/QTc interval as a biomarker for cardiac safety and the current guidelines for thorough QT/QTc studies which are mainly done to assess the pro-arrhythmic potential of a non-anti-arrhythmic drug.


Keywords


TQT study, Torsades de pointes

Full Text:

PDF

References


Li M, Ramos LG. Drug-Induced QT Prolongation And Torsades de Pointes. Pharm Ther. 2017;42:473-7.

QT interval and drug therapy (Clinical review from Drug and Therapeutics Bulletin). BMJ. 2016;354(4):i4331.

Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol. 2010;159:49-57.

Abraham J. International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In: Brouder A, Tietje C, editors. Handbook of Transnational Economic Governance Regimes. Brill. 2009;104154. http://booksandjournals.brillonl ine.com/content/books/10.1163/ej.9789004163300.i-1081.897. Accessed on 26 May, 2020.

Origin of the heartbeat and the Electrical Activity of the Heart. In: Barrett KE, Barman SM, Boitano S, Brooks HL. Ganong’s Review of Medical Physiology, 23rd ed. New York: McGraw-Hill. 2010;489-92.

Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89.

Research C for DE and. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. U.S. Food and Drug Administration. 2019. http://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0. Accessed on 27th May, 2020.

Lester RM, Paglialunga S, Johnson IA. QT Assessment in Early Drug Development: The Long and the Short of It. Int J Mol Sci. 2019;20:1324.

Mann DL, Zipes DP, Libby P, Bonow RO, Braunwal E. Evaluation of a patient. In: Braunwald's heart disease: A textbook of cardiovascular medicine. 10th ed. Philadelphia, PA. Elsevier/Saunders. 2015;124-5.

Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med. 2009;43:657-62.

Fauci L, Hauser K, Loscalzo J. Francis Macrchlinski. The Tachyarrhythmias. In: Harrison's Principles of Internal Medicine, 18th ed. New York Mc Graw- Hill. 2012;1890-3.

Priest BT, Bell IM, Garcia ML. Role of hERG potassium channel assays in drug development. Channels Austin Tex. 2008;2:87-93.

Darpo B, Nebout T, Sager PT. Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline. J Clin Pharmacol. 2006;46:498-507.

Research C for DE and. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry . U.S. Food and Drug Administration. 2019. http://www.fda.gov /regulatory-information/search-fda-guidance-docu ments/e14-clinical-evaluation-qtqtc-interval-prolon gation-and-proarrhythmic-potential-non-antiarrhythm ic-1. Accessed on 28th May 2020.

Malik M, Garnett C, Hnatkova K, Johannesen L, Vicente J, Stockbridge N. Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes. J Pharmacokinet Pharmacodyn. 2018;45:491-503.

Grenier J, Paglialunga S, Morimoto BH, Lester RM. Evaluating cardiac risk: exposure response analysis in early clinical drug development. Drug Healthc Patient Saf. 2018;10:27-36.

Shah RR. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol. 2010;159:58-69.

Malik M. Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation. Drug Saf. 2016;39(1):647-59.

Stockbridge N, Morganroth J, Shah RR, Garnett C. Dealing with Global Safety Issues. Drug Saf. 2013;36:167-82.

Georgia JLT, Crossman GRR. Drug-Induced QT Prolongation. https://www.uspharmacist.com/article/ drug-induced-qt-prolongation. Accessed 28th May, 2020.

Whellan JD, Green C, Piccini J, Krucoff WM. QT as a Safety Biomarker in Drug Development. Clin Pharmacol Ther. 2009;86:101-4.